DLK1 is a GATA1s-Driven Dependency and Therapeutic Target in Down Syndrome-Associated Myeloid Leukemia
Authors:
- Lonneke J. VerboonLVLonneke J. Verboon
- Sonali P. BarweSBSonali P. Barwe
- Joshua R. FaustJFJoshua R. Faust
- José Gonçalves-DiasJGJosé Gonçalves-Dias
- Konstantin SchuschelKSKonstantin Schuschel
- Raj BhayadiaRBRaj Bhayadia
- Patrick H. van BerkelPBPatrick H. van Berkel
- Aimy SebastianASAimy Sebastian
- Rhonda E RiesRRRhonda E Ries
- Sophie PaczesnySPSophie Paczesny
- Soheil MeshinchiSMSoheil Meshinchi
Preprint
Abstract
Myeloid leukemia associated with Down syndrome (ML-DS) is a rare pediatric cancer. Current standard-of-care includes cytotoxic chemotherapy. 10-20% of patients develop relapsed leukemia or have refractory disease. These patients have a 3-year event-free survival less than 21%. Novel therapy options are needed to improve survival in these patients with relapsed or refractory disease. Our transcriptome analysis to identify transmembrane proteins that are overexpressed in ML-DS compared to normal bone marrow specimens revealed DLK1 as one of the topmost modulated targets. We show that DLK1 knockout in ML-DS cells significantly reduced proliferation in vitro and delayed engraftment in vivo. Furthermore, targeting DLK1 via antibody drug conjugates significantly prolonged survival compared to control isotype antibody drug conjugate in patient-derived xenograft models of refractory ML-DS. Taken together, targeting DLK1 may be a novel treatment option for refractory ML-DS patients. Key Points We identified DLK1 as a novel target differentially expressed in myeloid leukemia associated with Down syndrome (ML-DS). DLK1-targeted antibody drug conjugate was effective in curbing leukemia progression in patient-derived xenograft models of refractory ML-DSKeywords
All Related Versions
- Published version: Blood Advances, 10 (12), 4120.
Funding Information
- Lisa Dean Moseley Foundation
- Leukemia Research Foundation of Delaware
- U.S. Department of War (W81XWH-22-1-0981)
- Nemours Foundation
- Deutsche Forschungsgemeinschaft (DFG; KL 2374/6-1)
- Hilfe für krebskranke Kinder Frankfurt
- Frankfurter Stiftung für krebskranke Kinder
- Mildred Scheel Career
This publication has 69 references indexed in Scilit:
- Down syndrome and leukemia: An insight into the disease biology and current treatment optionsBlood Reviews, 2023
- Leukemia Risk in a Cohort of 3.9 Million Children with and without Down SyndromeThe Journal of Pediatrics, 2021
- Delta-like 1 homolog (DLK1) as a possible therapeutic target and its application to radioimmunotherapy using 125I-labelled anti-DLK1 antibody in lung cancer models (HOT1801 and FIGHT004)Lung Cancer, 2021
- Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down SyndromeCancer Cell, 2019
- Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemiaLeukemia Research, 2017
- Low risk of solid tumors in persons with Down syndromeGenetics in Medicine, 2016
- Possible roles of DLK1 in the Notch pathway during development and diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012
- The EGF-like proteins DLK1 and DLK2 function as inhibitory non-canonical ligands of NOTCH1 receptor that modulate each other's activitiesBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- dlk acts as a negative regulator of Notch1 activation through interactions with specific EGF-like repeatsExperimental Cell Research, 2005
- Risks of leukaemia and solid tumours in individuals with Down's syndromeThe Lancet, 2000